Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229086 · ClinicalTrials.gov registry record
Gatekeeper European 005
A clinical trial, sponsored by MedtronicNeuro.
- Terminated
- Registry status
- 55
- Enrollment target
NCT00229086: Clinical Trial study, sponsored by MedtronicNeuro.
NCT00229086 is a clinical trial that was terminated before completion, run by MedtronicNeuro. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00229086 was terminated before completion, sponsored by MedtronicNeuro.
- TERMINATED
- Registry status
- 55 participants
- Enrollment target
Study Summary
Evaluation of the Gatekeeper System in the treatment of patients with Gastroesophageal Reflux Disease (GERD) who already have been treated under study protocols Endo 2000-03 and Endo 2000-04
Interventions
- DEVICE Gatekeeper Reflux Repari System (Device)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
Why NCT00229086 stopped before completion
NCT00229086 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gatekeeper Reflux Repari System (Device) is the first listed.
NCT00229086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00229086 about?
NCT00229086 is a clinical study titled "Gatekeeper European 005". Evaluation of the Gatekeeper System in the treatment of patients with Gastroesophageal Reflux Disease (GERD) who already have been treated under study protocols Endo 2000-03 and Endo 2000-04
What is the current status of trial NCT00229086?
This trial is currently terminated. The enrollment target is 55 participants.
What interventions are being tested in trial NCT00229086?
The interventions under investigation include: Gatekeeper Reflux Repari System (Device) (DEVICE).
Who is sponsoring clinical trial NCT00229086?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy